Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Got story updates? Submit your updates here. ›

Satellos Bioscience Inc., a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida. The presentations will feature data from a completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).

Why it matters

SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne and other degenerative or injury conditions. The presentations at the MDA conference will provide important updates on the progress of SAT-3247 as a potential disease-modifying treatment for DMD and potentially other muscle diseases.

The details

The oral presentations will feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with DMD, as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of FSHD. The poster presentations will cover the Phase 1a/b study, an upcoming Phase 2 study evaluating the long-term safety and efficacy of SAT-3247 in adults with DMD, and research on the regenerative potential in DMD.

• The 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference will take place from March 8-11, 2026 in Orlando, Florida.
• The oral presentations will be held on Wednesday, March 11, 2026.

What’s next

Satellos plans to provide more details on the scientific presentations and posters in a future press release and on its website.